1. Home
  2. LASR vs EWTX Comparison

LASR vs EWTX Comparison

Compare LASR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$64.73

Market Cap

3.7B

Sector

Technology

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$36.81

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
EWTX
Founded
2000
2017
Country
United States
United States
Employees
800
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.7B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
LASR
EWTX
Price
$64.73
$36.81
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$54.31
$39.00
AVG Volume (30 Days)
990.9K
1.7M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
62.99
N/A
EPS
0.01
N/A
Revenue
$191,359,000.00
N/A
Revenue This Year
$10.91
N/A
Revenue Next Year
$14.32
N/A
P/E Ratio
$6,488.00
N/A
Revenue Growth
38.09
N/A
52 Week Low
$16.87
$12.31
52 Week High
$86.95
$40.77

Technical Indicators

Market Signals
Indicator
LASR
EWTX
Relative Strength Index (RSI) 42.20 57.56
Support Level $63.48 $28.73
Resistance Level $71.81 $40.36
Average True Range (ATR) 5.43 2.61
MACD -0.84 -0.01
Stochastic Oscillator 24.88 60.15

Price Performance

Historical Comparison
LASR
EWTX

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: